Vitamin D3 and Immunity: Why Most UK Adults Are Deficient and What 46 RCTs Show About Respiratory Infections

Of all the nutritional factors influencing immune function, vitamin D3 occupies a unique position: its deficiency is near-universal in populations at northern latitudes for half the year, its immune consequences are severe and mechanistically well-understood, and its supplementation has now been tested in more randomised controlled trials than almost any other nutritional intervention in the respiratory infection space. Yet the majority of adults at highest risk — particularly those in the UK, Scandinavia, and northern Europe — enter winter without checking their levels or supplementing adequately.

Why Vitamin D Is Not Optional for Immune Function

Vitamin D is not merely a micronutrient with general health benefits. It is a signalling hormone — calcitriol (1,25-dihydroxyvitamin D3) — that directly regulates gene expression in immune cells through the vitamin D receptor (VDR). Critically, VDRs are expressed on virtually every immune cell type: T lymphocytes, B lymphocytes, natural killer cells, macrophages, dendritic cells, and neutrophils. This means vitamin D status directly influences the function of the entire immune system, not just a specific subset.

The primary immune mechanisms of vitamin D3 include:

• Cathelicidin and beta-defensin induction: Vitamin D3 is the primary inducer of cathelicidin — an antimicrobial peptide that directly destroys bacterial cell walls and disrupts viral envelopes. Respiratory epithelial cells (the first barrier encountered by inhaled pathogens) convert inactive vitamin D to its active form and use it to produce cathelicidin locally. Without adequate vitamin D, cathelicidin production in the respiratory tract is severely impaired — leaving the mucosal barrier significantly less able to neutralise airborne pathogens before they establish infection
• T cell differentiation: Vitamin D promotes the differentiation of naive T cells into regulatory T cells (Tregs) that suppress excessive inflammatory activation. Vitamin D deficiency shifts T cell balance toward Th1/Th17 dominance — increasing inflammatory tissue damage during infection without improving pathogen clearance
• NK cell activation: Vitamin D enhances natural killer cell cytolytic activity and IFN-gamma production — critical for early viral clearance during the innate immune response before adaptive immunity is fully engaged
• Macrophage function: Vitamin D enhances macrophage phagocytic capacity and stimulates the oxidative burst required to destroy phagocytosed pathogens

The Deficiency Crisis in Northern Populations

Vitamin D3 synthesis requires UVB radiation at a solar elevation angle above approximately 35 degrees — a condition that does not exist in the UK between approximately October and March. During these months, no meaningful vitamin D production occurs from sun exposure regardless of time spent outdoors. The consequences are dramatic:

• UK health surveys consistently find that 20–40% of adults are vitamin D deficient (below 25 nmol/L) in winter and spring, and the majority are insufficient (below 50 nmol/L)
• People with darker skin pigmentation require significantly longer sun exposure to produce equivalent vitamin D — making deficiency disproportionately severe in non-white populations in northern latitudes
• Adults over 65 have reduced dermal vitamin D synthesis capacity and often reduced dietary intake, making deficiency near-universal in this age group by February
• The UK government recommends universal vitamin D3 supplementation of 400 IU/day during autumn and winter — but this dose is insufficient to correct established deficiency, particularly in those starting from a very low baseline

The 2025 Lancet Meta-Analysis: 46 RCTs, 64,086 Participants

The most authoritative and up-to-date synthesis of the vitamin D and respiratory infection evidence was published in The Lancet Diabetes & Endocrinology in February 2025 (Jolliffe et al.). This updated meta-analysis incorporated 46 RCTs in a total of 64,086 participants — the largest individual participant data analysis in this field.

Key findings:

• Overall effect: Vitamin D supplementation significantly reduced acute respiratory infection risk (OR 0.92, 95% CI 0.86–0.99) — a statistically significant protective effect across the pooled population
• Dosing regimen matters critically: Protective effects were found with daily or weekly supplementation (OR 0.81, 95% CI 0.72–0.91) but not with bolus (infrequent high-dose) supplementation (OR 0.97, NS). This is a finding with major practical implications: taking a single large dose monthly or quarterly is ineffective; consistent daily supplementation is required
• Baseline deficiency amplifies benefit: In participants with severe deficiency at baseline (25(OH)D below 25 nmol/L), the protective effect was dramatic — OR 0.30 (95% CI 0.17–0.53), representing a 70% reduction in ARI risk. In those with higher baseline levels (≥25 nmol/L), effect was more modest but still significant (OR 0.75)

The 2024 Finnish Military Cohort: Deficiency Doubles Infection Risk

A 2024 RCT in Finnish military recruits (Laaksi et al., Open Forum Infectious Diseases) provided some of the clearest data on vitamin D insufficiency as an independent infection risk factor. In the follow-up study of 412 conscripts, those with vitamin D insufficiency at baseline (below 50 nmol/L) had:

• A 2.1-fold increased risk of experiencing two or more ARIs during the 14-week observation period
• A 2.3-fold increased risk of six or more days off duty due to ARI
• Lower cathelicidin concentrations — directly linking the infection susceptibility to the antimicrobial peptide mechanism

The RCT component found the supplementation dose used (800 IU/day) was insufficient to produce a statistically significant treatment effect — consistent with the Lancet meta-analysis finding that only doses effective at correcting deficiency, administered daily, produce meaningful immune protection.

What the Conflicting Evidence Tells Us

Some meta-analyses have found less consistent overall effects of vitamin D on respiratory infection. The 2024 Nutrition Journal meta-analysis of 43 RCTs found no significant overall protective effect (RR 0.99). This apparent contradiction is resolved by understanding heterogeneity: the trials that show no effect are predominantly in populations that were not deficient at baseline, used bolus dosing, or used doses insufficient to meaningfully raise vitamin D levels. The benefit of supplementation is concentration-dependent — it corrects a deficiency that impairs a fundamental immune mechanism, rather than supraphysiologically enhancing a normal one.

Practical Protocol: Testing, Dosing, and Optimising

• Test first (ideally): A 25(OH)D blood test in September/October reveals baseline status before winter. Most GPs offer this, or private finger-prick tests are available. Target range for immune function: 75–150 nmol/L
• Dose by status: If levels are 25–50 nmol/L (insufficient): 2,000 IU/day to correct and maintain. If below 25 nmol/L (deficient): 4,000 IU/day for 8–12 weeks then reduce to 2,000 IU/day maintenance. If above 75 nmol/L: 1,000 IU/day maintenance through winter
• Daily not bolus: The evidence consistently shows daily or weekly supplementation works; monthly or quarterly bolus doses do not produce the same immune benefit
• With vitamin K2: High-dose D3 supplementation increases calcium absorption; vitamin K2 (MK-7 form, 100–200mcg/day) directs this calcium into bone rather than soft tissue. Standard co-supplementation at doses above 2,000 IU/day
• With fat: Vitamin D3 is fat-soluble — take with the day's largest meal for best absorption